Bioscan licenses IDSI molecular imaging technology

AuntMinnie.com staff writers

Sep 4, 2006

CT laser mammography (CTLM) developer Imaging Diagnostic Systems (IDSI) has licensed its laser optical imaging technology to molecular imaging developer Bioscan of Washington, DC.

The Plantation, FL-based IDSI said that it granted Bioscan an exclusive worldwide license to manufacture and distribute optical imaging equipment incorporating its Laser Imager for Lab Animals (LILA) technology.

Under terms of the agreement, Bioscan will pay an up-front license fee and royalty payments as the technologies are commercialized. IDSI will transfer its small animal optical computed tomography (CT) technology, including licensing 10 issued U.S. patents, and three pending patents for optical CT imaging.

By AuntMinnie.com staff writers
September 5, 2006

Related Reading

IDSI gets Colombian sale, August 8, 2006

IDSI adds second Czech order, August 1, 2006

IDSI adds third Polish sale, June 13, 2006

Bioscan displays NanoSPECT/CT animal imager, June 7, 2006

IDSI begins clinical trials, May 1, 2006

Copyright © 2006 AuntMinnie.com

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$

Can AI improve sustainability in nuclear medicine?

April 9, 2024

Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)

The rise of theranostics: Part 2 -- Moving into communities

April 4, 2024

Driving the future of PET/CT.

Driving the future of PET/CT.

April 17, 2024

Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)

The rise of theranostics: Part 1 -- Gaining momentum

March 26, 2024

Can AI improve sustainability in nuclear medicine?

Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.

April 9, 2024

ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.

The rise of theranostics: Part 2 -- Moving into communities

In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.

April 4, 2024

Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)

SNMMI to tackle Capitol Hill

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) will host its annual Hill Day on April 5 in Washington, DC.

April 3, 2024

The rise of theranostics: Part 1 -- Gaining momentum

FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.

March 26, 2024

Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)

Cannabis may influence bowel motility

Physicians, health care providers, and medical staff caring for patients who use cannabis should be familiar with the effects of the drug on gut motility, a recent report advises.

March 11, 2024

Hold off on the Egg McMuffins before GES tests, experts say

Nuclear medicine technologists are being advised that not just any meal works for patients before gastric emptying scintigraphy (GES).

March 7, 2024

Neiman HPI publishes advanced imaging prediction index

By Kate Madden Yee

The Harvey L. Neiman Health Policy Institute (HPI) has developed and released a comorbidity index designed to help predict use of advanced imaging.

January 25, 2024

2018 08 14 19 14 9213 Neiman Hip 400

IBA celebrates sale of the 100th Cyclone Kiube cyclotron

By AuntMinnie.com staff writers

Ion Beam Applications (IBA) is celebrating the sale of the 100th Cyclone Kiube cyclotron.

December 21, 2023

PET predicts chemotherapy responses in breast cancer patients

PET/CT with gallium-68 FAPI radiotracer can predict responses to neoadjuvant chemotherapy in breast cancer patients.

November 8, 2023

Representative Ga-68 FAPI-PET/CT images of 48-year-old woman who had left invasive ductal carcinoma and who achieved pathologic complete response (pCR). (A) Baseline maximum-intensity projection (MIP) image demonstrated primary lesion (red arrowhead; SUVmax, 26.72) and Ga-68 FAPI-avid lymph node in left axilla (red arrows). (B) MIP image after two cycles of neoadjuvant chemotherapy (NAC) showed that primary lesion (red arrowhead; SUVmax, 8.87) and axillary lymph nodes (red arrow) were reduced in size and radioactivity uptake. (C and D) Representative images of lab tissue staining for FAP before NAC showed strong FAP-positive staining in stromal cells (C), which was significantly decreased on tumor bed after six cycles of NAC (D). Image courtesy of the Journal of Nuclear Medicine.

FAPI-PET bests FDG-PET in detecting gastrointestinal cancer

Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer.

October 31, 2023

Nine representative patients who underwent F-18 FDG and F-18 FAPI-74 PET imaging. F-18 FAPI-74 PET outperforms F-18 FDG-PET in detecting primary tumors (patients 11, 39, 50, 58, 79, and 101; solid black arrows), local recurrences (patient 4; blue arrows), abdomen LN metastases (patients 4 and 50; green arrows), intrahepatic metastases (patient 50; red arrows), bone metastases (patient 85; arrowheads), and peritoneal metastases (patients 4, 11, 85, 97, and 101; dotted arrows). Image courtesy of the Journal of Nuclear Medicine.

PET reveals patient responses to new Alzheimer’s disease drug

Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab.

October 27, 2023

Pediatric PET radiotracer doses drop by a third over two decades

Over the past 20 years, children have benefited from a massive reduction in PET imaging radiotracer doses without compromise in image quality.

October 20, 2023

Page 1 of 436